PROTAC ER Degrader-2 is an intermediate for synthesis of PAC. PAC comprises an antibody conjugated via a linker to a PROTAC. PAC extracts from patent WO2017201449A1, compound LP2. PAC is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).
[1]. Thomas Pillow, et al. Protac antibody conjugates and methods of use. WO2017201449A1.
















